SRI-37330
Based on 6 publication(s) in Google Scholar
SRI-37330 is an orally bioavailable thioredoxin-interacting protein (TXNIP) inhibitor. SRI-37330 inhibits glucagon secretion and function, reduces hepatic glucose production and reverses hepatic steatosis. SRI-37330 can be used for type 2 diabetes research.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity : 99.16%
- CAS No.: 2322245-42-9
- 화학식: C16H19F3N4O2S
- 분자량:388.41
-
보관:
4°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- Protocol
- 순도&문서
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) SRI-37330
More
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
WB
-
Bio/Physico-chemical Assay
-
RT-PCR
-
Cell Imaging/Staining
All Arrestin Isoforms
More
Biological Activity
제품 설명
IC50 & Target
TXNIP[1]
In Vitro
SRI-37330 (1 μM, 24 h) inhibits the activity of the human TXNIP promoter in INS-1 cells[1].
SRI-37330 (1 μM, 24 h) inhibits Mrna and protein levels of TXNIP in INS-1 cells[1].
SRI-37330 (5 μM, 24 h) inhibits polymerase II (Pol II) binding to the E-box motif region of the TXNIP promoter[1].
SRI-37330 (5 μM, 24 h) lowers glucagon secretion in TC1-6 cells[1].
SRI-37330 (0-5 μM, 24 h) inhibits glucagon-induced glucose output from primary hepatocytes[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:INS-1 cells
-
Concentration:1 μM
-
Incubation Time:24 h
-
Result:Inhibited endogenous TXNIP mRNA expression with an IC50 of 0.64 μM.
In Vivo
SRI-37330 (100 mg/kg, p.o., in drinking water, 3 weeks) is well tolerated in male C57BL/6J mice[1].
SRI-37330 (100 mg/kg, p.o., in drinking water, 3 weeks) reverses obesity- and STZ-induced diabetes and hepatic steatosis in mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J mice[1]
-
Dosage:100 mg/kg
-
Administration:Oral administration (p.o.), in drinking water, 3 weeks.
-
Result:Lowered serum glucagon levels, inhibited hepatic glucose production and improved glucose homeostasis in mice.
Chemical Information
-
CAS No. 2322245-42-9
-
Appearance Solid
-
분자량 388.41
-
화학식 C16H19F3N4O2S
-
Color White to off-white
-
SMILES
CS(=O)(NCC1CN(C2=C3C=C(C(F)(F)F)C=CC3=NC=N2)CCC1)=O
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
4°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
Publications (6)
-
Journal Impact Factor
-
Most Recent
-
-
Cell Death Dis
TXNIP upregulation controls metabolism and cell cycle during androgen deprivation therapy in prostate cancer. [Abstract]2025 Nov 10;16(1):817. PMID: 41213907 -
J Biochem Mol Toxicol
Sesamol Alleviated Lipotoxicity-Induced Dysfunction in MIN6 Cells via Facilitating Cellular Senescence Caused by Endoplasmic Reticulum Stress. [Abstract]2024 Nov;38(11):e70038. PMID: 39470143
SRI-37330 purchased from MedChemExpress. Usage Cited in: J Biochem Mol Toxicol. 2024 Nov;38(11):e70038. [Abstract]
Based on the results, the insulin content in both the MIN6 cells and the supernatant were decreased by PA intervention and then were elevated in the presence of SRI-37330.
SRI-37330 purchased from MedChemExpress. Usage Cited in: J Biochem Mol Toxicol. 2024 Nov;38(11):e70038. [Abstract]
Relative to the PA group, upregulations were observed in the level of Ins2 mRNA, PDX-1, and MAFA after SRI-37330 (1 μM) treatment.
SRI-37330 purchased from MedChemExpress. Usage Cited in: J Biochem Mol Toxicol. 2024 Nov;38(11):e70038. [Abstract]
We found that SRI-37330 attenuated cellular senescence in PA-treated MIN6 cells.
SRI-37330 purchased from MedChemExpress. Usage Cited in: J Biochem Mol Toxicol. 2024 Nov;38(11):e70038. [Abstract]
We found that SRI-37330 attenuated cellular senescence in PA-treated MIN6 cells.
-
Exp Eye Res
Resveratrol protects lens epithelial cells and delays cataract development via inhibiting TXNIP mediated oxidative stress and apoptosis. [Abstract]2026 Jun:267:110969. PMID: 41864488
SRI-37330 purchased from MedChemExpress. Usage Cited in: Exp Eye Res. 2026 Jun:267:110969. [Abstract]
Cell survival rates at different concentrations of SRI37330.
SRI-37330 purchased from MedChemExpress. Usage Cited in: Exp Eye Res. 2026 Jun:267:110969. [Abstract]
The results showed that resveratrol and SRI37330 exerted similar effects on the expression of related proteins, suppressed TXNIP protein expression, and upregulated Trx2 expression level.
-
Biomed Pharmacother
Mitigation of nicotine-induced podocyte injury through inhibition of thioredoxin interacting protein. [Abstract]2025 Jun:187:118110. PMID: 40311224 -
용액&용해도
In Vitro:
DMSO : 100 mg/mL (257.46 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 5 mg/mL (12.87 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
-
Data Sheet (282 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.5746 mL | 12.8730 mL | 25.7460 mL | 64.3650 mL |
| 5 mM | 0.5149 mL | 2.5746 mL | 5.1492 mL | 12.8730 mL | |
| 10 mM | 0.2575 mL | 1.2873 mL | 2.5746 mL | 6.4365 mL | |
| 15 mM | 0.1716 mL | 0.8582 mL | 1.7164 mL | 4.2910 mL | |
| 20 mM | 0.1287 mL | 0.6436 mL | 1.2873 mL | 3.2182 mL | |
| 25 mM | 0.1030 mL | 0.5149 mL | 1.0298 mL | 2.5746 mL | |
| 30 mM | 0.0858 mL | 0.4291 mL | 0.8582 mL | 2.1455 mL | |
| 40 mM | 0.0644 mL | 0.3218 mL | 0.6436 mL | 1.6091 mL | |
| 50 mM | 0.0515 mL | 0.2575 mL | 0.5149 mL | 1.2873 mL | |
| 60 mM | 0.0429 mL | 0.2145 mL | 0.4291 mL | 1.0727 mL | |
| 80 mM | 0.0322 mL | 0.1609 mL | 0.3218 mL | 0.8046 mL | |
| 100 mM | 0.0257 mL | 0.1287 mL | 0.2575 mL | 0.6436 mL |
SRI-37330 Related Classifications
HY-142114 Related Classifications
Powered by Bioz